Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation

European Journal of Pharmacology

Volumn 546, Issue 1-3, 2006, Pages 142-147

  Wu, Chin Chung ^a   Teng, Che Ming ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Platelet activation; Protease activated receptor; Thrombin

Indexed keywords

1 BENZYL 3 (ETHOXYCARBONYLPHENYL) INDAZOLE; N [3 AMINO 1 [[(PHENYLMETHYL)AMINO]CARBONYL]PROPYL] ALPHA [[[[[1 (2,6 DICHLOROPHENYL)METHYL] 3 (1 PYRROLIDINYLMETHYL) 1H INDOL 6 YL]AMINO]CARBONYL]AMINO] 3,4 DIFLUOROBENZENEPROPANAMIDE; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 4; PROTEINASE ACTIVATED RECEPTOR 4 ANTAGONIST; RECEPTOR BLOCKING AGENT; RWJ 56110; THROMBIN; THROMBIN RECEPTOR; UNCLASSIFIED DRUG; YD 3;

ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

BLOOD PLATELETS; CROTALID VENOMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INDAZOLES; OLIGOPEPTIDES; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PYRROLES; QUINAZOLINES; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; THROMBIN; UREA;

EID: 33748307543     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.07.004     Document Type: Article

References (28)

1. Adam F., Verbeuren T.J., Fauchere J.L., Guillin M.C., and Jandrot-Perrus M. Thrombin-induced platelet PAR4 activation: role of glycoprotein Ib and ADP. J. Thromb. Haemost. 1 (2003) 798-804
2. Ahn H.S., Foster C., Boykow G., Stamford A., Manna M., and Graziano M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem. Pharmacol. 60 (2000) 1425-1434
3. Andrade-Gordon P., Derian C.K., Maryanoff B.E., Zhang H.C., Addo M.F., Cheung W.M., Damiano B.P., D'Andrea M.R., Darrow A.L., de Garavilla L., Eckardt A.J., Giardino E.C., Haertlein B.J., and McComsey D.F. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. 298 (2001) 34-42
4. Bernatowicz M.S., Klimas C.E., Hartl K.S., Peluso M., Allegretto N.J., and Seiler S.M. Development of potent thrombin receptor antagonist peptides. J. Med. Chem. 39 (1996) 4879-4887
5. Cook J.J., Sitko G.R., Bednar B., Condra C., Mellott M.J., Feng D.M., Nutt R.F., Shafer J.A., Gould R.J., and Connolly T.M. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 91 (1995) 2961-2971
6. Covic L., Gresser A.L., and Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39 (2000) 5458-5467
7. Covic L., Singh C., Smith H., and Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb. Haemost. 87 (2002) 722-727
8. De Candia E., Hall S.W., Rutella S., Landolfi R., Andrews R.K., and De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR-1 on intact platelets. J. Biol. Chem. 276 (2001) 4692-4698
9. Derian C.K., Damiano B.P., Addo M.F., Darrow A.L., D'Andrea M.R., Nedelman M., Zhang H.C., Maryanoff B.E., and Andrade-Gordon P. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J. Pharmacol. Exp. Ther. 304 (2003) 855-861
10. Dubois C., Steiner B., Kieffer N., and Reigner S.C. Thrombin binding to GPIbα induces platelet aggregation and fibrin clot retraction supported by resting alphaIIbbeta3 interaction with polymerized fibrin. Thromb. Haemost. 89 (2003) 853-865
11. Faruqi T.R., Weiss E.J., Shapiro M.J., Huang W., and Coughlin S.R. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J. Biol. Chem. 275 (2000) 19728-19734
12. Hollenberg M.D., and Saifeddine M. Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can. J. Physiol. Pharmacol. 79 (2001) 439-442
13. Jandrot-Perrus M., Bouton M.C., Lanza F., and Guillin M.C. Thrombin interaction with platelet membrane glycoprotein Ib. Semin. Thromb. Hemost. 22 (1996) 151-156
14. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., and Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 103 (1999) 879-887
15. Kahn M.L., Zheng Y.W., Huang W., Bigornia V., Zeng D., Moff S., Farese Jr. R.V., Tam C., and Coughlin S.R. A dual thrombin receptor system for platelet activation. Nature 394 (1998) 690-694
16. Kato Y., Kita Y., Nishio M., Hirasawa Y., Ito K., Yamanaka T., Motoyama Y., and Seki J. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur. J. Pharmacol. 384 (1999) 197-202
17. Ruggeri Z.M. Platelets in atherothrombosis. Nat. Med. 8 (2002) 1227-1234
18. Sambrano G.R., Weiss E.J., Zheng Y.W., Huang W., and Coughlin S.R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413 (2001) 74-78
19. Schneider D.J., Taatjes D.J., and Sobel B.E. Paradoxical inhibition of fibrinogen binding and potentiation of α-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc. Res. 45 (2000) 437-446
20. Shapiro M.J., Weiss E.J., Faruqi T.R., and Coughlin S.R. Protease-activated receptor 1 and 4 are shutoff with distinct kinetics after activation by thrombin. J. Biol. Chem. 275 (2000) 25216-25221
21. Soslau G., Class R., Morgan D.A., Foster C., Lord S.T., Marchese P., and Ruggeri Z.M. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J. Biol. Chem. 276 (2001) 21173-21183
22. 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb. Res. 88 (1997) 137-146
23. Vandendries E.R., Furie B.C., and Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb. Haemost. 92 (2004) 459-466
24. Wu C.C., Huang S.W., Hwang T.L., Kuo S.C., Lee F.Y., and Teng C.M. YD-3, a novel inhibitor of protease-induced platelet activation. Br. J. Pharmacol. 130 (2000) 1289-1296
25. Wu C.C., Hwang T.L., Liao C.H., Kuo S.C., Lee F.Y., Lee C.Y., and Teng C.M. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb. Haemost. 87 (2002) 1026-1033
26. Wu C.C., Hwang T.L., Liao C.H., Kuo S.C., Lee F.Y., and Teng C.M. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb. Haemost. 90 (2003) 299-308
27. Wu W.B., Peng H.C., and Huang T.F. Crotalin, a vWF and GP Ib cleaving metalloproteinase from venom of Crotalus atrox. Thromb. Haemost. 86 (2001) 1501-1511
28. Xu Y., Huo Y., Toufektsian M.C., Ramos S.I., Ma Y., Tejani A.D., French B.A., and Yang Z. Activated platelets contribute importantly to myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H692-H699